Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
The EMBO Journal|December 21, 2022
WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structuresValentina Mengoli, Ilaria Ceppi, Aurore Sanchez, et al.
Plos One|July 5, 2012
Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cellsAngelo Cerbone, Cristina Toaldo, Rosalba Minelli, et al.
PPAR Research|May 24, 2012
AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer CellsAngelo Cerbone, Cristina Toaldo, Stefania Pizzimenti, et al.
Free Radical Biology & Medicine|August 6, 2011
Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cellsPiergiorgio Pettazzoni, Eric Ciamporcero, Claudio Medana, et al.
ACS Chemical Biology|September 26, 2019
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer PathwayPhilipp Ottis, Chiara Palladino, Phillip Thienger, et al.
Free Radical Biology & Medicine|November 17, 2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cellsPiergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, et al.
The Biochemical Journal|June 11, 2009
Exposure of HL-60 human leukaemic cells to 4-hydroxynonenal promotes the formation of adduct(s) with alpha-enolase devoid of plasminogen binding activityFabrizio Gentile, Stefania Pizzimenti, Alessia Arcaro, et al.
Molecular Cancer Therapeutics|December 4, 2025
Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancerFlorian Renner, Jan Eckmann, Cornelia Handl, et al.
Atherosclerosis|July 6, 2011
PPARγ in coronary atherosclerosis: in vivo expression pattern and correlations with hyperlipidemic status and statin treatmentAngela Pucci, Luisa Formato, Maruska Muscio, et al.
Free Radical Biology & Medicine|May 18, 2016
GSH-targeted nanosponges increase doxorubicin-induced toxicity "in vitro" and "in vivo" in cancer cells with high antioxidant defensesMartina Daga, Chiara Ullio, Monica Argenziano, et al.
Pageof 4